MYOCOR ™
MYOCOR 2.5 MG TABLET | |
---|---|
Generic : | Bisoprolol |
Thearapeutic : | Cardiovascular Drug |
Pack Size : | 30s |
Strength : | |
Dosage Form : | Tablet |
Myocor
Bisoprolol Fumarate
Composition
- Myocor 2.5 mg tablet: Each film-coated tablet contains Bisoprolol Fumarate USP 2.5 mg.
- Myocor 5 mg tablet: Each film-coated tablet contains Bisoprolol Fumarate USP 5 mg.
Description
- Bisoprolol Fumarate is a beta 1-selective (cardioselective) adrenoceptor-blocking agent without significant membrane stabilizing activity or intrinsic sympathomimetic activity in its therapeutic dosage range.
Indications
- Bisoprolol Fumarate is indicated in the treatment of hypertension, angina, and heart failure. It may be used alone or in combination with other antihypertensive agents.
Dosage and administration
- The usual starting dose is 2.5 mg once daily. If the antihypertensive effect is inadequate, the dose may be increased to 10 mg and then, if necessary, to 20 mg once daily.
For heart failure
Initially, 1.25 mg once daily (in the morning) for 1 week then, if well tolerated, increased to 2.5 mg once daily for 1 week, then 3.75 mg once daily for 1 week, then 5 mg once daily for 4 weeks, then 7.5 mg once daily for 4 weeks, then 10 mg once daily; max. 10 mg daily.
Use in Pregnancy and Lactation
- Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Bisoprolol Fumarate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nursing Mothers
- Small amounts of bisoprolol fumarate (< 2% of the dose) have been detected in the milk of lactating rats. It is not known whether this drug is excreted in human milk. As because of many drugs are excreted in human milk caution should be exercised when bisoprolol fumarate is administered to nursing women.
Side-effects
Diarrhea, dizziness, drowsiness, fatigue, headache, nausea, sleeplessness, unusual tiredness, weakness, Severe allergic reactions (rash, hives, itching, difficulty breathing, tightness in the chest, swelling of the mouth, face, lips, or tongue), chest pain, difficulty breathing, lightheadedness or dizziness when rising from a lying or sitting position, very slow heartbeat.
Precautions
- Impaired Renal or Hepatic Function.
Contraindications
- Bisoprolol is contraindicated in patients with cardiogenic shock, over-cardiac failure, the second or third degree of AV block, and marked sinus bradycardia.
Drug interactions
Bisoprolol Fumarate should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs should be closely monitored, because the added -beta-adrenergic blocking action of Bisoprolol Fumarate may produce an excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, It is suggested that Bisoprolol Fumarate be discontinued for several days before the withdrawal of clonidine. Bisoprolol Fumarate should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists or antiarrhythmic agents are used concurrently. Concomitant use with digitalis glycosides can increase the risk of bradycardia. Concurrent use of rifampin increases the metabolic clearance of Bisoprolol Fumarate, resulting in a shortened elimination- half-life of Bisoprolol Fumarate. However, initial dose modification is generally not necessary.
Overdosage
The most common signs expected with overdosage of beta-blockers are bradycardia, hypotension, congestive heart failure, bronchospasm, and hypoglycemia. To date, a few cases of overdose (maximum: 2000 mg) with bisoprolol fumarate have been reported. Bradycardia and/or hypotension were noted. Sympathomimetic agents were given in some cases, and all patients recovered. In general, if an overdose occurs, bisoprolol fumarate therapy should be stopped and supportive and symptomatic treatment should be provided. Limited data suggest that bisoprolol fumarate is not dialyzable. Based on the expected pharmacologic actions and recommendations for other beta-blockers, the following general measures should be considered when clinically warranted.
Commercial Pack
- Myocor 2.5 mg Tablet: Each box contains 3 blister packs of 10 tablets.
- Myocor 5 mg Tablet: Each box contains 3 blister packs of 10 tablets.
Biopharma Ltd. Produces MYOCOR 2.5 MG TABLET it is a trusted product for alleviating various discomforts, and it's commonly found in pharmacies and stores.